School of Life Science, Tsinghua University, 100084, Beijing, China.
High Performance Computing Department, National Supercomputing Center in Shenzhen, Shenzhen, 518055, Guangdong, China.
Commun Biol. 2022 Aug 15;5(1):822. doi: 10.1038/s42003-022-03778-y.
Cancer cells evolve various mechanisms to overcome cellular stresses and maintain progression. Protein kinase R (PKR) and its protein activator (PACT) are the initial responders in monitoring diverse stress signals and lead to inhibition of cell proliferation and cell apoptosis in consequence. However, the regulation of PACT-PKR pathway in cancer cells remains largely unknown. Herein, we identify that the long non-coding RNA (lncRNA) aspartyl-tRNA synthetase antisense RNA 1 (DARS-AS1) is directly involved in the inhibition of the PACT-PKR pathway and promotes the proliferation of cancer cells. Using large-scale CRISPRi functional screening of 971 cancer-associated lncRNAs, we find that DARS-AS1 is associated with significantly enhanced proliferation of cancer cells. Accordingly, knocking down DARS-AS1 inhibits cell proliferation of multiple cancer cell lines and promotes cancer cell apoptosis in vitro and significantly reduces tumor growth in vivo. Mechanistically, DARS-AS1 directly binds to the activator domain of PACT and prevents PACT-PKR interaction, thereby decreasing PKR activation, eIF2α phosphorylation and inhibiting apoptotic cell death. Clinically, DARS-AS1 is broadly expressed across multiple cancers and the increased expression of this lncRNA indicates poor prognosis. This study elucidates the lncRNA DARS-AS1 directed cancer-specific modulation of the PACT-PKR pathway and provides another target for cancer prognosis and therapeutic treatment.
癌细胞进化出各种机制来克服细胞应激并维持进展。蛋白激酶 R(PKR)及其蛋白激活剂(PACT)是监测多种应激信号的最初反应者,因此导致细胞增殖和细胞凋亡的抑制。然而,PKR-PACT 通路在癌细胞中的调控仍知之甚少。在此,我们发现长非编码 RNA(lncRNA)天冬氨酰-tRNA 合成酶反义 RNA 1(DARS-AS1)直接参与抑制 PACT-PKR 通路,并促进癌细胞的增殖。通过对 971 种与癌症相关的 lncRNA 的大规模 CRISPRi 功能筛选,我们发现 DARS-AS1 与癌细胞的显著增殖增强有关。相应地,敲低 DARS-AS1 可抑制多种癌细胞系的细胞增殖,并促进体外癌细胞凋亡,并显著减少体内肿瘤生长。在机制上,DARS-AS1 直接与 PACT 的激活结构域结合,防止 PACT-PKR 相互作用,从而减少 PKR 激活、eIF2α 磷酸化并抑制凋亡性细胞死亡。临床上,DARS-AS1 在多种癌症中广泛表达,该 lncRNA 的表达增加表明预后不良。本研究阐明了 lncRNA DARS-AS1 对 PACT-PKR 通路的特异性癌症调节作用,并为癌症预后和治疗提供了另一个靶点。